جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

15 مُخرَج نتائج البحث عن «Dosing»

مراجعةمفتوح (مستودع)2026

Comparative Efficacy and Safety of Intranasal Opioids versus Intravenous Morphine for Acute Moderate-to-Severe Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Journal of Emergency Medicine

Background Intranasal (IN) opioids may provide non-invasive analgesia without delays associated with intravenous (IV) access, but their efficacy and safety versus IV morphine remain uncertain. Objectives To synthesize randomized evidence comparing IN opioids with IV morphine for acute moderate-to-severe pain. Methods PubMed, Scopus, Web of Science, and the Cochrane Library were searched from inception to May 2026 for randomized controlled trials (RCTs) in adults or children with acute moderate-to-severe pain in emergency, prehospital, procedural, or postoperative settings. Eligible trials directly compared IN opioids with IV morphine. The primary outcome was change in pain score from baseline at 20 and 30 minutes. Secondary outcomes included rescue analgesia and adverse events. Outcomes were pooled as standardized mean differences (SMD) or risk ratios (RR) using random-effects models. Results Ten RCTs involving 1,164 participants were included. IN opioids showed comparable analgesic efficacy to IV morphine at 20 minutes (SMD = −0.05, 95% CI: −0.24 to 0.14; p = 0.59; I² = 11.94%) and 30 minutes (SMD = −0.05, 95% CI: −0.24 to 0.15; p = 0.64; I² = 0.00%). Rescue analgesia was comparable (RR = 1.00, 95% CI: 0.81 to 1.25; p = 0.98). No significant differences were observed in overall adverse events, serious adverse events, respiratory complications, hypotension, gastrointestinal events, dizziness, or rhinorrhea. Dysgeusia was borderline increased. Conclusion IN opioids provide analgesic efficacy comparable to IV morphine at 20 and 30 minutes, with no clear increase in systemic adverse events. Larger trials should confirm safety for rare serious events and optimize dosing.

intravenous morphineanalgesic efficacyadverse eventsrescue analgesia
مقالوصول مفتوح2026

Efficacy and long-term impact of HPV vaccination strategies: A Scoping review of clinical trials and follow-up studies

Pharmacy Practice · مجلد 23 (4) · 1-6

Background: Human papillomavirus (HPV) is a leading cause of cervical cancer and other HPV-related cancers globally. Vaccination against HPV has proven to be a pivotal intervention in reducing the burden of these diseases. However, questions remain regarding long-term efficacy, dosing strategies, and real-world outcomes of HPV vaccines. Objective: We aim to synthesise evidence from randomised controlled trials and long-term follow-up studies on the efficacy, immunogenicity, safety, and real-world impact of HPV vaccines. Methodology: A comprehensive search was conducted in PubMed, Cochrane Library, Embase, Scopus, and Web of Science for studies published in English from 2019 to 2024. Eligible studies included randomised controlled trials and long-term follow-up analyses focusing on HPV vaccine efficacy, dosing regimens, and population-specific outcomes. Data were extracted and synthesised narratively, with findings organised into five thematic areas. Results: Seventeen studies met the inclusion criteria. Findings confirm the high efficacy of HPV vaccines in preventing HPV-related cancers and precancers, with durable immunogenicity observed up to 12 years post-vaccination. Evidence supports the potential of single-dose regimens, which could improve accessibility in resource-limited settings. Real-world data demonstrated significant reductions in HPV-related diseases across diverse populations, reinforcing the global impact of HPV vaccination programs. Conclusion: This review highlights the critical role of HPV vaccines in reducing the burden of HPV-related cancers, with robust efficacy, long-term protection, and favourable safety profiles. The findings underscore the need for continued research into optimised vaccination strategies and the expansion of global vaccination efforts.

HPV vaccinationhuman papillomaviruscervical cancer preventionHPV-associated cancers
مراجعةمفتوح (مستودع)2026

The Impact of Body Weight on Aspirin’s Antiplatelet Efficacy: A Narrative Review of Conflicting Evidences and Clinical Implications

Advanced Health Science and Technology Journal · مجلد 2 (1) · 21-26

Abstract Aspirin is one of the oldest and most used anti-platelet medications for the prevention of cardiovascular diseases. There has been conflicting research recently about how body weight affects the antiplatelet effectiveness of aspirin. The purpose of this narrative review was to examine the recent research on the connection between aspirin responsiveness, platelet function, and obesity. To find patterns and discrepancies, pertinent research from PubMed, Scopus, and Google Scholar was rigorously examined and compiled. While some studies showed no discernible effect, others highlighted methodological and population-specific variations by reporting decreased aspirin efficacy in people with higher body weight because of increased platelet reactivity, aspirin deactivation, and altered pharmacokinetics, underscoring the need for well-designed, large-scale clinical investigations. The need for carefully planned, extensive clinical studies is highlighted by the fact that the evidence is still equivocal overall. A better understanding of these mechanisms may support the development of personalized antiplatelet strategies, including tailored aspirin dosing in selected subgroups such as obese patients with high thrombotic risk.

aspirinbody weightobesityantiplatelet efficacy
مراجعةوصول مفتوح202526استشهاد· Semantic Scholar

Exploring the Safety and Efficacy of Glutathione Supplementation for Skin Lightening: A Narrative Review

Cureus · مجلد 17 (1) · e78045-e78045

The rising demand for skin-lightening products has brought glutathione, a tripeptide with antioxidant properties and melanogenesis-regulating effects, into focus as a potentially safer alternative to conventional agents. This narrative review aims to evaluate the efficacy and safety of oral, topical, and intravenous glutathione in skin-lightening therapies. Oral administration shows significant but variable decreases in melanin levels with limited side effects. Topical formulations provide good-level melanin reduction and skin texture improvement but with varying sustainability. Intravenous glutathione, although having rapid action, is associated with serious safety concerns like anaphylaxis and hepatotoxicity, further aggravated by a lack of standardized dosing protocols. Current evidence supports glutathione's potential as a depigmenting agent but underscores the need for rigorous, large-scale clinical trials to establish long-term safety, optimal dosing, and standardized applications. Until such data are available, clinicians and consumers should exercise caution to ensure safe and effective dermatological practices, particularly with intravenous use.

glutathioneskin lighteningdepigmentationmelanogenesis
مقالوصول مفتوح20256استشهاد· Semantic Scholar

Parthanatos drives cognitive decline in repeated brain trauma: MSC-derived exosomes as a novel therapeutic strategy

Frontiers in Pharmacology · مجلد 16 · 1622018-1622018

Introduction: Repetitive traumatic brain injury (RTBI) represents a cumulative neurological insult associated with progressive neurodegeneration and limited therapeutic options. In this study, we uniquely evaluate the neuroprotective potential of mesenchymal stem cell (MSC)-derived exosomes in a rat model of RTBI, an area scarcely explored. Methods: RTBI was induced via a controlled mechanical impact to the skull once every day for 5 days. MSC-derived exosomes were administered 24 h after the final insult in two paradigms: a single dose (MSC-Ex1) with 2 weeks of follow-up, and a dual dose (MSC-Ex2) given 1 week apart, with sacrifice 1 week later. Rats were assigned to four groups: control, RTBI, RTBI + MSC-Ex1, and RTBI + MSC-Ex2. Results: MSC-derived exosome regimens comparably restored cognitive performance in the Novel Object Recognition and Y-maze tests. While both treatment paradigms preserved cortical histoarchitecture, the double-dose regimen led to a more pronounced restoration compared to the moderate tissue recovery observed in the single-dose group. Crucially, this work identifies parthanatos inhibition as a novel mechanistic axis for MSC-derived exosomes-mediated neuroprotection. MSC-derived exosomes attenuated excitotoxicity and oxidative stress, quelling the parthanatos cascade by suppressing PARP1, PAR polymers, nuclear AIF and MIF, as well as calpain, key executors of this caspase-independent cell death pathway. Additionally, MSC-derived exosomes normalized cyclophilin B and Hsp70 levels, suggesting their compensatory role in modulating the endogenous stress response. Conclusion: Overall, these findings demonstrate that MSC-derived exosomes counteract RTBI-induced neurodegeneration through multifaceted mechanisms, with parthanatos suppression at the core. Importantly, the dual-dosing regimen conferred no significant benefit over the single dose, highlighting the therapeutic promise of early intervention. This study positions MSC-derived exosomes as a novel, cell-free therapy capable of intercepting RTBI-induced neuropathology by targeting an under recognized form of programmed cell death.

repetitive traumatic brain injuryparthanatosmesenchymal stem cell-derived exosomescognitive decline
مقالوصول مغلق20256استشهاد· Semantic Scholar

Development and evaluation of mucoadhesive buccal films for sustained release of glipizide using natural proteins

Drug Development and Industrial Pharmacy · مجلد 51 (8) · 930-942

PURPOSE: To address the challenges of frequent glipizide dosing, including its variable bioa-vailability and gastrointestinal side effects, this study developed and evaluated mucoadhesive buccal films using natural proteins (albumin, gelatin, casein) combined with HPMC E15 to achieve sustained drug delivery. METHODS: Nine formulations (F1-F9) were prepared using solvent casting technique and sys-tematically characterized. Comprehensive evaluations included: (1) drug-polymer compatibil-ity studies (FT-IR, DSC), (2) physicochemical characterization (thickness, weight uniformity, swelling index, moisture content, folding endurance, surface pH), (3) ex-vivo permeation studies through sheep buccal mucosa, and (4) stability assessments to determine film longevi-ty. RESULTS: Compatibility studies utilizing FT-IR and DSC confirmed no significant incompati-bility between glipizide and the excipients. Some of the important physicochemical character-istics recorded for different formulations were surface pH (6.6 - 6.8), folding endurance (72 - 184), moisture content (5.66 - 12.54%), thickness (0.171 - 0.236 mm), weight (0.150 - 0.238 mg), and swelling index (15.8% after 1 hour to 86.6% after 5 hours). Furthermore, neg-ligible variation was observed in these characteristics when stability studies were conducted after 3 months. The ex-vivo permeation studies demonstrated a sustained release of glipizide over 8 hours, with release percentages ranging from 80.94% to 90%. Formulation F6, which achieved an 8-hour release of 89.29%, was identified as optimal. Kinetic analysis revealed zero-order release kinetics for all formulations. CONCLUSION: The developed mucoadhesive buccal films exhibited excellent sustained-release properties, representing a significant improvement over conventional dosage forms. This in-novative delivery system shows strong potential for enhancing diabetes management through improved bioavailability and patient compliance, while minimizing gastrointestinal side effects.

mucoadhesive buccal filmsglipizidesustained drug releasenatural proteins
مقالوصول مفتوح20254استشهاد· Semantic Scholar

Real-World Off-Label Use of Semaglutide for Weight Reduction: User Behavior, Effectiveness, and Satisfaction

Patient Preference and Adherence · مجلد Volume 19 · 3373-3385

Background: for weight loss has surged in the Arab populations in the absence of structured real-world evaluation. Objective: To assess utilization patterns, effectiveness, and patient satisfaction with off-label Ozempic use for weight reduction across Arab populations. Methods: A cross-sectional survey was conducted using a validated bilingual questionnaire. Data included demographics, source of initiation, dose escalation, treatment duration, weight changes, and satisfaction. Analyses examined associations between demographics, treatment initiation source, dose escalation adherence, weight loss, and satisfaction. Results: Analysis included 626 users. Nearly one-third of users (30.6%) self-initiated Ozempic, most based on independent self-learning and social media. Most (72.4%) used Ozempic solely for weight reduction, with a further 20.1% for both weight loss and diabetes control. About two thirds (69.3%) started at the recommended 0.25 mg dose, significantly more often in users with physician-led initiation (p<0.05). Only 20.3% followed standard dose escalation. Of those who stopped Ozempic, 59.7% discontinued the drug early before reaching 12 weeks of use including 4 weeks at the 1.0 mg dose. Among those who discontinued, treatment duration was longer in users with physician-led initiation. Despite erratic use, reported mean weight loss by 8-12 weeks exceeded 5% in most subgroups, with no statistically significant differences across 0.25, 0.5, and 1.0 mg doses. Satisfaction, reported by 56.5% of users, was positively correlated with weight loss and shifted into the positive satisfaction level at an estimated weight reduction of 11.6%. Conclusion: Off-label Ozempic use in Arab populations is characterized by widespread self-initiation, irregular dosing, and early discontinuation. Nonetheless, clinically meaningful weight loss was achieved in many users. These findings emphasize the need for structured counseling to optimize outcomes.

semaglutideoff-label drug useweight lossobesity
مقالمفتوح (مستودع)2025

Exosomes versus Platelet-rich Plasma in Hair Loss Therapy: A Comprehensive Literature Review

Journal of Advanced Trends in Medical Research · مجلد 2 (4) · 671-681

Hair loss, or alopecia, encompasses a diverse range of conditions including both cicatricial (scarring) and non-cicatricial (non-scarring) forms, with significant implications for patients’ physical appearance, psychological well-being and overall quality of life. The limitations of traditional therapies such as topical agents, oral medications and hair transplantation have led to increasing interest in regenerative approaches. Amongst these, platelet-rich plasma (PRP) and exosome-based therapies have emerged as promising biologic interventions. PRP, derived from autologous blood, contains a high concentration of platelets rich in growth factors that support hair follicle regeneration, angiogenesis and cellular proliferation. Evidence suggests its potential benefits in various types of hair loss particularly androgenetic alopecia, alopecia areata and telogen effluvium, although standardised protocols, optimal dosing and long-term outcomes remain uncertain. Exosomes are small extracellular vesicles secreted by stem cells that offer a novel cell-free alternative capable of delivering complex molecular signals to modulate inflammation, stimulate follicular stem cells, and promote dermal remodeling. Early findings indicate possible applications across a range of alopecias including chemotherapy-induced hair loss, autoimmune related alopecia and structural hair shaft disorders such as trichorrhexis nodosa and monilethrix. This narrative review provides an updated overview of PRP and exosome-based therapies, outlining their mechanisms of action, clinical applications and current limitations. While both modalities show therapeutic promise, their biologic variability, lack of regulatory standardisation and need for comparative trials highlight critical gaps in evidence. Further research is warranted to establish reproducible treatment protocols and determine long-term efficacy and safety for clinical use.

hair lossplatelet-rich plasmaexosomesextracellular vesicles
مقالوصول مفتوح202435استشهاد· Semantic Scholar

Development and optimization of vildagliptin solid lipid nanoparticles loaded ocuserts for controlled ocular delivery: A promising approach towards treating diabetic retinopathy

International Journal of Pharmaceutics X · مجلد 7 · 100232-100232

Diabetes mellitus (DM) is the most prevalent cause of diabetic retinopathy (DRP). DRP has been recognized for a long time as a microvascular disease. Many drugs were used to treat DRP, including vildagliptin (VLD). In addition to its hypoglycemic effect, VLD minimizes ocular inflammation and improves retinal blood flow for individuals with type 2 diabetes mellitus. Nevertheless, VLD can cause upper respiratory tract infections, diarrhea, nausea, hypoglycemia, and poor tolerability when taken orally regularly due to its high water solubility and permeability. Effective ocular administration of VLD is achieved using solid lipid nanoparticles (SLNPs), which improve corneal absorption, prolonged retention, and extended drug release. Ocuserts (OCUs) are sterile, long-acting ocular dosage forms that diminish the need for frequent dosing while improving residence time and stability. Therefore, this study intends to develop VLD solid lipid nanoparticle OCUs (VLD-SLNPs-OCUs) to circumvent the issues commonly associated with VLD. SLNPs were prepared using the double-emulsion/melt dispersion technique. The optimal formula has been implemented in OCUs. Optimization and development of VLD-SLNPs-OCUs were performed using a Box-Behnken Design (BBD). VLD-SLNPs-OCUs loading efficiency was 95.28 ± 2.87%, and differential scanning calorimetry data (DSC) showed the full transformation of VLD to an amorphous state and the excellent distribution in the prepared OCUs matrices. The in vivo release of VLD from the optimized OCUs after 24 h was 35.12 ± 2.47%, consistent with in vitro drug release data of 36.89 ± 3.11. The optimized OCUs are safe to use in the eye, as shown by the ocular irritation test. VLD-SLNPs-OCUs provide extended VLD release, an advantageous alternative to conventional oral dose forms, resulting in fewer systemic adverse effects and less variation in plasma drug levels. VLD-SLNPs-OCUs might benefit retinal microvascular blood flow beyond blood glucose control and may be considered a promising approach to treating diabetic retinopathy.

vildagliptinsolid lipid nanoparticlesOcusertocular drug delivery
مقالوصول مفتوح202395استشهاد· Semantic Scholar

Anticancer, antioxidant, ameliorative and therapeutic properties of kaempferol

International Journal of Food Properties · مجلد 26 (1) · 1140-1166

Kaempferol, found in various plants and foods, has gained attention as a useful flavonoid owing to its potential biological properties, including anticancer characteristics. Recent research studies suggest that kaempferol is effective in the inhibition and treatments of several forms of cancer, e.g. lung, ovarian, breast and lung cancer. One probable mechanism of action of kaempferol is its anti-inflammatory and antioxidant potentials, which may help to prevent DNA damage and inhibit the proliferation of cancerous cells. Besides triggering apoptosis in cancerous cells, Kaempferol may also inhibit the growth and relocation of cancerous cells. Moreover, kaempferol has a very wide range of bioactivities, involving anti-inflammatory and antioxidant effects. This includes understanding the optimal dosing and timing of kaempferol treatment, as well as the potential interactions with other medications and the long-term safety of kaempferol use. Overall, the available evidence and studies suggest that kaempferol may provide a potential natural agent for the prevention and treatments of cancers. Despite the promising findings in preclinical and clinical research, further research is needed to confirm its efficacy and understand the mechanisms of action, and to fully explore the potential of kaempferol in different cancers.

kaempferolflavonoidsanticancer activityantioxidant activity
مقالوصول مفتوح20231استشهاد· Semantic Scholar

Real-world Experience in Managing Atrial Fibrillation in Patients with Renal Impairment; Rivaroxaban versus Warfarin

Heart Views · مجلد 24 (3) · 136-140

Background: The use of rivaroxaban in patients with atrial fibrillation (AF) and chronic kidney disease (CKD) poses the risk of over- or underdosing. We aimed to compare rivaroxaban and warfarin in AF patients with moderate and severe renal impairment. Methods: This retrospective study was conducted between 2015 and 2016 to compare the use of warfarin ( n = 164) and rivaroxaban ( n = 149) in patients with AF and moderate or severe CKD. The study outcomes were survival, stroke, and major bleeding events. The median follow-up was 50 months (interquartile range: 23–60). Results: Thirty-six patients had major bleeding: 24 with rivaroxaban and 12 with warfarin ( P = 0.01). The rivaroxaban group had major bleeding in 3 patients with moderate CKD, 4 with severe CKD, and 17 on dialysis. Multivariable analysis of factors affecting major bleeding revealed that warfarin use lowered the risk of bleeding (hazard ratio: 0.34; P = 0.004). Stroke occurred in 14 patients: 6 in the rivaroxaban group and 8 in the warfarin group ( P = 0.44). Survival at 1, 3, and 5 years was 89%, 77%, and 71% with warfarin and 99%, 94%, and 88% with rivaroxaban, respectively ( P < 0.001). Multivariable analysis showed higher mortality in patients with lower creatinine clearance and those on warfarin. Conclusions: The safety of warfarin could be better than rivaroxaban in patients with CKD with fewer bleeding complications but similar stroke rates. Further studies on rivaroxaban dosing in patients on dialysis are required.

atrial fibrillationchronic kidney diseaserenal dysfunctionrivaroxaban
مقالوصول مفتوح2023

Better survival in morbidly obese patients with atrial fibrillation treated with non-vitamin K-dependent oral anticoagulants

Journal of the Saudi Heart Association · مجلد 35 (1) · 7-15

Background: The efficacy and safety of non-vitamin K-dependent anticoagulants (NOAC) are not well investigated in the obese population, and fixed dosing could lead to under-anticoagulation. Our objective was to evaluate the effect of obesity on anticoagulation outcomes and survival in non-valvular atrial fibrillation (AF) patients. Methods: We enrolled 755 patients who required anticoagulation for AF from 2015 to 2016. We grouped the patients into four groups. Group 1 (n = 297) included patients with BMI< 40 kg/m2 treated with NOACs, Group 2 (n = 358) included patients on warfarin with BMI< 40 kg/m2, Group 3 (n = 57) had patients on NOACs with BMI≥ 40 kg/m2 and Group 4 (n = 43) included patients on warfarin and BMI≥ 40 kg/m2. Study outcomes were the composite endpoint of stroke, bleeding, and survival. Results: Competing risk regression showed that stroke and bleeding were not affected by obesity or treatment (SHR: 1.09 (95% CI: 0.79-1.51); P = 0.62). Older age was the predictor of stroke/bleeding (HR:1.03 (95% CI:1.01-1.06); P = 0.02). Predictors of mortality were heart failure (HR:2.23 (95% CI:1.25-3.97); P = 0.007), lower creatinine clearance (HR: 0.98 (95% CI:0.97-0.98): P < 0.001), non-obese patients on warfarin (HR:3.51 (95%CI:1.6-7.7): P = 0.002) and obese patients on warfarin (HR: 6.7 (95% CI:2.51-17.92); P < 0.001). Conclusion: NOACs could have a similar risk profile to warfarin in obese and non-obese patients with non-valvular AF but could have better survival. Larger randomized trials are recommended.

morbid obesitynon-valvular atrial fibrillationwarfarinsurvival
مقالوصول مفتوح20211استشهاد· Semantic Scholar

Urgent need to standardize labelling of acetaminophen-paediatric liquid drug products in Saudi Arabia

International Journal of Pediatrics and Adolescent Medicine · مجلد 9 (1) · 62-65

In this study, dosing instructions in package inserts of all 12 paediatric liquid acetaminophen products registered in pharmacies in the Kingdom of Saudi Arabia were analysed to determine the potential for administering a supratherapeutic dose of acetaminophen. Doses in millilitres were calculated as mg/kg for four age groups: three months old, one year old, six years old, and twelve years old, and based on the 3rd, 50th, and 75th weight percentiles of each age group. Acetaminophen concentrations in the products varied, and only two products included Arabic language instructions. The dosing instructions in eight products included an age overlap. The most affected age group was the 1-year-old group, with 21 supratherapeutic doses across all 12 products. The least affected age group was the 12-year-old group, with 8 supratherapeutic doses in total. The absence of strict supervision and monitoring of labels of paediatric liquid acetaminophen products increases the risk of liver toxicity in children. Therefore, we call for an immediate standardisation of all dosing instructions regarding the dose per weight and the inclusion of instructions in Arabic.

paracetamoldrug labelingdosing instructionssupratherapeutic dose
مقالوصول مفتوح20204استشهاد

Sleep pattern and dozing chance among university students

Journal of Family Medicine and Primary Care · مجلد 9 (12) · 6249-6249

BACKGROUND: Sleep is defined as a naturally occurring state of the body within a relatively inhibited sensory activity, reduced metabolic rate and decreased interaction with the surrounding. Impaired sleep affects students' productivity, this area is not fully covered in the literature. OBJECTIVES: To assess sleep patterns and dozing chance among university students. METHODS: Institutional based cross-sectional study, a sample of 145 male university students from Almaarefa University aged between 19 and 27 years old, chosen randomly. A self-administered questionnaire developed specifically for this study after consulting literature and epidemiologist. It includes data about the Epworth Sleepiness scale and GPA. Data were analyzed using (SPSS, version 22.0) and (P values of ≤0.05) considered significant. The consent was obtained before data collection. RESULTS: The majority of respondents (62, 1%) reported sleeping time of 5-8 hours per night. To fall asleep at night 13, 1% of participants indicated needing soporific. Overall, only 36, 6% of students showed good sleep behaviors. Among respondents (44, 1%) had moderate chances of dozing and 2, 8% had high chances of dozing, There was no significant statistical relationship between academic performance and bedtime (P-value = 0,231). CONCLUSION: The majority of respondents had poor sleep quality and moderate to high dosing chance, also, most of the participants go to bed after midnight. In addition, one fifth of participants reported sleeping less than 8 hour per day.

sleep patternsdaytime sleepinessuniversity studentssleep quality
مقالمفتوح (مستودع)20195استشهاد

Physicochemical, pharmacokinetics, and histological evaluation of new naproxen-quercetin co-lyophilizate to diminish drug-induced gastric irritations in rats

Saudi Pharmaceutical Journal · مجلد 27 (3) · 413-421

Quercetin (QUE) is a flavonoid found in several plants and commonly distributed in edible vegetables and fruits. To evaluate the effect of co-lyophilization of naproxen (NPX) with QUE at different weight ratios on physicochemical characteristics induced gastric irritation, and drug pharmacokinetics. NPX binary systems with QUE in different weight ratios were prepared by freeze-drying alkalinized solutions, and were characterized in terms of physicochemical properties as well as NPX dissolution rate in acidic pH. NPX-induced gastric inflammation studies were carried out in rats for 7 days. The pharmacokinetics of the two formulations were assessed to evaluate the bioavailability of NPX-QUE 1:2 co-lyophilizate. Westar rats were administered oral doses equivalent to 40 mg kg −1 of NPX and blood samples were taken from the retro-orbital vein of rats at 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0 12.0, and 24.0 h post dosing. Co-lyophilization of NPX with QUE enhanced drug dissolution rate in the acidic medium, which was correlated with an increased QUE weight ratio in the co-lyophilizates. Rat stomachs from group V (NPX-QUE 1:2 co-lyophilizate) showed non-significant changes, and biopsies from this group showed no significant leukocyte infiltration and edema in the mucosa. The bioavailability of NPX-QUE 1: 2 co-lyophilizate was similar to the control sample. NPX-QUE 1: 2 co-lyophilizate could be an alternative to NPX in the treatment of arthritis as it minimizes the potential for gastric irritation and enhances safety while retaining the same efficacy and bioavailability.

naproxenquercetinfreeze-dryinggastritis